Xtandi (enzalutamide) plus ADT significantly slows disease progression vs darolutamide plus ADT in patients with mHSPC, according to a matching-adjusted indirect comparison analysis published in Future Oncology.
A mother’s mitochondria determines if lactation is protective or not against breast cancer—and points to a possible intervention to increase the benefit to more women, according to a pre-clinical study conducted by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Spatial mapping experiments reveal that topologically associating domains in individual cells tend to take a globular shape, according to a study conducted by scientists at Sanford Burnham Prebys and colleagues in Hong Kong.
FDA has granted Priority Review to TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
Chinese authorities granted the marketing authorization for Braftovi (encorafenib) in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.
Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.
The U.S. Department of Health and Human Services last week cancelled a scheduled meeting of the U.S. Preventive Services Task Force, a 16-member panel that writes guidelines for screening and prevention based on the principles of evidence-based medicine.
Unless you were sleeping under a rock, you are aware of the coordinated attacks on Iran’s nuclear facilities by Israel and the United States.
Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.1,2
The U.S. Supreme Court has temporarily lifted a lower court’s freeze on the Trump administration’s reductions in force, or RIFs, freeing the government to continue their large-scale restructuring of the federal government.
